Seikagaku licenses lumbar disc herniation product to Kaken

13 May 2012

Japanese companies Seikagaku Corp (TYO: 4548) and Kaken Pharmaceutical (TYO: 4521) have concluded a basic agreement concerning exclusive marketing rights in Japan for SI-6603 (condoliase), indicated for treatment of lumbar disc herniation. The companies plan to execute a final agreement at the end of 2012. No financial terms of the accord have as yet been disclosed.

Seikagaku is conducting clinical development of SI-6603 in Japan and the USA. In Japan, the product is in Phase III clinical trial. Seikagaku aims to promptly conduct this trial so as to obtain approval in the shortest possible time.

Characteristics of SI-6603

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK